INFORMATION ON VACCINATION-DIFFERENTIATED SAFE MANAGEMENT MEASURES (SMMS)

[NEW UPDATES]
From 1 Jun 2022, recovered persons who had completed their primary series vaccination would need to receive the booster dose to maintain their vaccinated status. Please refer to the MOH Press Release on 22 April 2022 for more details.

From 26 April 2022, vaccination-differentiated SMMs will be removed from all settings, except for events with more than 500 participants at any one time, nightlife establishments where dancing among patrons is an intended activity, and food and beverage establishments. Please refer to the MOH Press Release on 22 April 2022 for more details.

1. Vaccination-differentiated SMMs for vaccinated individuals have been implemented since 10 August 2021 for selected premises, activities and events. The list of settings where vaccination-differentiated SMMs are required can be found in Annex A.

2. Vaccination-differentiated SMMs enable higher-risk activities to resume in a safe manner as we progressively open our economy and community. We have eased measures for those who are fully vaccinated because they have good protection against infection and are at lower risk of becoming dangerously ill if infected with COVID-19. On the other hand, unvaccinated individuals will need to be more prudent in interacting with larger groups of people especially in mask-off settings, which are higher risk. Hence stricter measures are applied to protect them.

3. Where vaccination-differentiated SMMs are required, event organisers and relevant enterprises must implement processes to carry out the necessary verification checks on the eligibility status of individual event attendees and customers, in addition to existing safe management requirements, unless otherwise specified in Annex A.

4. The following categories of individuals are allowed to enter premises or participate in activities where vaccination-differentiated SMMs are required:

   a. Fully vaccinated,
      i. i.e. has received the appropriate regimen of World Health Organisation Emergency Use Listing (WHO EUL) COVID-19 vaccines (e.g. Pfizer-BioNTech/Comirnaty, Moderna/Spikevax, AstraZeneca/Vaxzevria, Serum Institute of India/Covishield, Janssen, Sinopharm, Sinovac-CoronaVac, Covaxin,
Novavax/Nuvaxovid and CanSinoBIO/Convidecia) including their respective duration post-vaccination for the vaccine to be fully effective and boosters for eligible individuals (please refer to the requirements to be considered fully vaccinated in Annex B), and had their vaccination records ingested in the National Immunisation Registry (NIR); or

ii. Recovered from COVID-19 in Singapore, i.e. persons with positive Polymerase Chain Reaction (PCR) test result and persons with positive Antigen Rapid Test (ART) result obtained at approved test providers and have completed their vaccination regime including boosters¹;

b. Recovered from COVID-19 in Singapore with unvaccinated or incomplete vaccinated status within 180 days starting from the day of the first local
   i. positive PCR test result, or
   ii. positive ART result obtained at approved test providers; or
   iii. positive serology test result attributable to infection and not past vaccination.

c. Children who are 12 years old and below, i.e. born in or after the year 2010, who are unvaccinated, are also eligible for vaccination-differentiated SMMs.

d. Individuals who are certified to be medically ineligible for all vaccines under the National Vaccination Programme that currently include Pfizer-BioNTech/Comirnaty, Moderna/Spikevax, Sinovac-CoronaVac and Novavax/Nuvaxovid COVID-19 vaccines will be eligible for vaccination-differentiated SMMs. To be certified as medically ineligible, individuals may visit a doctor familiar with their medical condition, or alternatively, any clinic or hospital.

5. Individuals who deliberately misrepresent their eligibility status and/or that of others (e.g. including but not limited to the provision of false or misleading verification documents and/or information) may be subject to enforcement action under the Penal Code, Infectious Diseases Act and/or other COVID-19 legislation.

6. Where vaccination-differentiated SMMs are required, event organisers and relevant enterprises must ensure that attendees and customers meet the eligibility

¹ The fully vaccinated status will take effect 14 days after the last dose of vaccine for these persons: (a) persons recovered from a COVID-19 infection and subsequently received at least one dose of COVID-19 vaccine (two doses if Sinovac/Sinopharm) authorised under the Health Sciences Authority’s Pandemic Special Access Route or listed on the World Health Organisation’s Emergency Use Listing (WHO EUL) no earlier than 3 months after date of positive PCR test or healthcare-administered ART; (b) persons who completed primary series vaccination regime, i.e. 2 doses with WHO EUL vaccines except Sinovac/Sinopharm, or 3 doses of Sinovac/Sinopharm, before being infected with COVID-19 and subsequently recovering from it. The fully vaccinated status will be valid for 270 days from the last dose, or 180 days after the last locally documented infection, whichever is later (see Annex B, Table 2d). Persons described in (a) and (b) will need to receive the booster dose to maintain their vaccinated status beyond the validity period.
requirements stated in para 4 above. Please refer to Annex C for more details on the modes of verification for vaccination-differentiated SMMs.

7. Event organisers or relevant enterprises that are required to implement vaccination-differentiated SMMs should refer to Annex D for processes to be implemented. The use of the SafeEntry (Business) App is strongly encouraged to facilitate eligibility checks for both TraceTogether App and Token users. The SafeEntry Gateway Box cannot be used to facilitate these checks. For more information on using SafeEntry (Business) App for vaccination-differentiated checks, please refer to https://go.gov.sg/status-check.

Annex A – List of Settings with Vaccination-Differentiated SMMs
Annex B – Vaccination Requirements for Completion of COVID-19 Vaccine Course
Annex C – Modes of Verification for Vaccination-Differentiated SMMs
Annex D – Processes to Be Implemented by Event Organisers and Relevant Enterprises Implementing Vaccination-Differentiated SMMs

MINISTRY OF HEALTH
UPDATED ON: 1 Jun 2022
**Annex A**

**List of Settings with Vaccination-Differentiated SMMs**

From 26 Apr 2022, these are the settings where Vaccination-Differentiated SMMs will apply.

<table>
<thead>
<tr>
<th>Higher-risk activities</th>
<th>Vaccination-Differentiated SMMs required for all participants/customers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Events (if &gt;500 participants at any one time)</strong></td>
<td></td>
</tr>
<tr>
<td>Business events (e.g. MICE events)</td>
<td>✓</td>
</tr>
<tr>
<td>Spectator and participatory sports events</td>
<td>✓</td>
</tr>
<tr>
<td>Live performances</td>
<td>✓</td>
</tr>
<tr>
<td>Congregational and worship services</td>
<td>✓</td>
</tr>
<tr>
<td>Media conferences</td>
<td>✓</td>
</tr>
<tr>
<td>Nuptial events (Solemnisations and wedding receptions)</td>
<td>✓</td>
</tr>
<tr>
<td>Other events (e.g. birthday and anniversary celebrations, funerary memorial events*)</td>
<td>✓</td>
</tr>
</tbody>
</table>

| Settings                                                                                |                                                                       |
| *Food and beverage (F&B) establishments including restaurants, coffee shops, hawker centres | ✓                                                                     |
| Bars, casinos and karaoke establishments                                                |                                                                       |
| Nightlife establishments where dancing among patrons is one of the intended activities (e.g. nightclubs and discotheques) | ✓                                                                     |

^ exclude funerals, funeral wakes or funeral processions

*Note: Specific to F&B establishments, bars, casinos and karaoke establishments, while VDS is still required, these establishments will no longer need to conduct VDS checks for their customers. Instead, the onus will be on the individuals dining in to abide by the rules. Random spot-checks by enforcement agencies and enterprises will continue to be conducted to ensure that only fully vaccinated persons are dining-in at these establishments.
Annex B

Vaccination Requirements for Completion of COVID-19 Vaccine Course

Individuals may be considered fully vaccinated if they meet the following conditions:

(I) Primary vaccination series
Completed the COVID-19 primary vaccination series (as detailed in Pages 9 – 11 below), and have their vaccination records ingested in the National Immunisation Registry (NIR).
Travellers who are recognised as having taken the full regimen of World Health Organization Emergency Use Listing (WHO EUL) vaccines outside of Singapore will be reflected as fully vaccinated for 30 days upon their first arrival, for the purposes of entering premises subject to VDS. If their stay in Singapore exceeds 30 days, they will need to have their vaccination records ingested into Singapore’s NIR, and may be required to receive additional doses to continue to meet Singapore’s requirements for vaccination.

Notes 1:
• For partially completed course with Sinovac-Coronavac or Sinopharm: (1) those with 2 doses or (2) those with heterologous vaccine regimes [1 dose WHO Emergency Use Listing (EUL) + 1 dose Sinovac-Coronavac/Sinopharm]
  o Can be accepted if vaccination satisfies the above minimum first intervals; and
  o Validity will expire at 120 days from the second dose.
• Persons who took 2 doses are required to take the 3rd dose to complete vaccine course.
• Travellers to Singapore with 2 doses of Sinovac-Coronavac/Sinopharm will be granted valid status of 30 days regardless of when they had taken their vaccinations as their country may not have adopted a 3-dose primary series yet.
• Please refer to the First Schedule of the Infectious Diseases (COVID-19 Access Restrictions and Clearance) Regulations 2021 for the most updated information on the vaccination regimens and approved vaccines recognised for eligibility for vaccination-differentiated SMMs.

(II) Booster vaccination
• For the purposes of the vaccination-differentiated SMMs, a person is considered boosted if a WHO EUL vaccine dose was received on or beyond 90 days after the last dose of a complete primary series vaccination (see Notes 2).
• From 14 February 2022, those aged 18 years and above who have completed the COVID-19 primary vaccination series and are eligible for booster vaccination will be considered as fully vaccinated for 270 days (9 months) after their last dose in the primary vaccination series. Upon receiving their booster, they will continue to be considered fully vaccinated beyond the 270 days.
• From 14 March 2022, persons aged 12 to 17 years who have completed their primary series of vaccines and are eligible for booster vaccination will similarly be considered fully vaccinated for only 270 days (9 months) after their last primary
series dose, and will require a booster dose to maintain their vaccinated status thereafter.

- From 1 Jun 2022, recovered persons aged 12 and above who have completed their primary vaccination series and are eligible for booster will require a booster dose to maintain their vaccinated status beyond 270 days (9 months) after the last vaccine dose in their primary vaccination series (see Table 2d).

Notes 2:

- Persons who had received a vaccine dose less than 90 days after the last dose of a primary vaccination series would not be considered to have received a booster. In such cases, the 270-day validity of the primary series will be counted from the last vaccine dose received after the completion of a primary vaccination series that is not a booster dose. They would need to receive another dose from at least 90 days after the completion of the primary vaccination series to be considered boosted.

- For more information on booster vaccinations, please visit https://www.moh.gov.sg/covid-19/vaccination/faqs---booster-doses.
# Table 1: Vaccination Recommendations Under the National Vaccination Programme

## Primary Vaccination Recommendations

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Name of Vaccine</th>
<th>Doses for Completed Primary Series</th>
<th>Recommended Interval Between Primary Doses</th>
<th>Interval from Completion of Primary Vaccination to Start of Vaccination Status</th>
<th>Recommended Interval to Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer-BioNTech</td>
<td>BNT162b2/Comirnaty® Tozinameran (INN)</td>
<td>2 Doses</td>
<td>21 days</td>
<td>14 days</td>
<td>Around 5 months</td>
</tr>
<tr>
<td>Moderna</td>
<td>mRNA-1273/Spikevax</td>
<td>2 Doses</td>
<td>28 days</td>
<td>14 days</td>
<td>Around 5 months</td>
</tr>
<tr>
<td>Sinovac</td>
<td>COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™</td>
<td>3 Doses</td>
<td>Interval between Dose 1 and Dose 2: 28 days Interval between Dose 2 and Dose 3: 90 days</td>
<td>14 days, after Dose 2. Status valid for 120 days. Immediate after the 3rd dose</td>
<td>3 months</td>
</tr>
<tr>
<td>Novavax</td>
<td>NVX-CoV2373/Covovax™/Nuvaxovid™</td>
<td>2 doses</td>
<td>21 days</td>
<td>14 days</td>
<td>Around 5 months</td>
</tr>
</tbody>
</table>

## Booster Vaccination Recommendations

Individuals who have completed primary vaccination are recommended to receive a booster vaccine dose at the intervals recommended in the table above. The booster vaccine can be either a booster dose of the Pfizer-BioNTech/Comirnaty vaccine (30 micrograms) or the Moderna/Spikevax vaccine (50 micrograms). The Sinovac-CoronaVac vaccine should only be considered for booster vaccination in persons who are medically ineligible for the mRNA vaccines and the Novavax/Nuvaxovid vaccine.

## Vaccination Recommendations for Individuals with a Documented Past COVID-19

Individuals who have a documented past infection from COVID-19 are recommended to receive one dose of an mRNA vaccine (Pfizer-BioNTech/Comirnaty or Moderna/SpikeVax) if they were unvaccinated or partially vaccinated at the time of the infection to complete their primary vaccination series. From 7 June
2022, these persons will be considered fully vaccinated for 270 days from the last vaccine dose of their primary vaccination series. They would need to receive a booster dose to maintain their vaccinated status beyond 270 days (see Table 2d). The above does not apply to individuals who tested positive after self-testing on an antigen-rapid test, who are recommended to complete the regular recommended primary series and booster vaccination.

**Vaccination Status for Vaccination-Differentiated Safe Management Measures**

Individuals who have their completed primary vaccinations are granted a 'Vaccinated status' that is valid till 270 days after the last dose of the primary vaccination series. They are required to receive a booster dose in order to maintain their 'Vaccinated status' beyond the 270 days.

**Table 2a: Primary vaccination recommendations and minimum acceptable dose intervals for vaccines available in Singapore**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Name of Vaccine</th>
<th>Doses for Complete Vaccine Course</th>
<th>Recommended Interval Between Doses*</th>
<th>Minimum Acceptable Interval Between Doses^</th>
<th>Interval from Completion of Primary Vaccination to Start of Valid Vaccination Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer/BioNTech</td>
<td>BNT162b2/Comirnaty® Tozinameran (INN)</td>
<td>2 doses</td>
<td>21 days</td>
<td>17 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>Moderna</td>
<td>mRNA-1273/Spikevax</td>
<td>2 doses</td>
<td>28 days</td>
<td>24 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>Novavax</td>
<td>NVX-CoV2373/Covovax™/Nuvaxovid™</td>
<td>2 doses</td>
<td>21 days</td>
<td>17 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>Sinovac</td>
<td>COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™</td>
<td>3 doses</td>
<td>Interval between Dose 1 and Dose 2: 28 days# Interval between Dose 2 and Dose 3: 90 days</td>
<td>Interval between Dose 1 and Dose 2: 13 days Interval between Dose 2 and Dose 3: 17 days</td>
<td>14 days after Dose 2 - status valid for 120 days. Immediately after the Dose 3 – status valid for 270 days~</td>
</tr>
</tbody>
</table>
Sinopharm
SARS-CoV-2 Vaccine (VeroCell), Inactivated (InCoV) 3 doses
Interval between Dose 1 and Dose 2: 21 days
Interval between Dose 2 and Dose 3: 90 days
Interval between Dose 1 and Dose 2: 17 days
Interval between Dose 2 and Dose 3: 17 days
14 days after Dose 2 - status valid for 120 days. Immediately after the Dose 3 – status valid for 270 days.

* Based on national recommendations by the Expert Committee on COVID-19 Vaccination
# Based on the WHO SAGE Interim Recommendations for COVID-19 vaccines under Emergency Use Listing
~ Vaccination status valid until 270 days after the last dose of the primary series. A booster dose of a WHO EUL vaccine should be received at around 5 months after completion of the primary series (3 months if the last dose was a Sinovac-CoronaVac or Sinopharm vaccine) to extend the validity of vaccination status to beyond 270 days. The booster dose should be received no less than 90 days after the completion of the primary series.
^ Grace period of 4 days provided for most recommended intervals.

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Name of Vaccine</th>
<th>Doses for Complete Vaccine Course</th>
<th>Recommended Interval Between Doses*</th>
<th>Minimum Acceptable Interval Between Doses^</th>
<th>Interval from Completion of Primary Vaccination to Start of Valid Vaccination Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrazeneca</td>
<td>Vaxzeveria/AZD1222(ChAdOx1-S)</td>
<td>2 doses</td>
<td>28 days or greater</td>
<td>24 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>Serum Institute of India</td>
<td>Covishield™ (ChAdOx1-S)</td>
<td>2 doses</td>
<td>28 days or greater</td>
<td>24 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>Janssen</td>
<td>Ad26.COV2-S</td>
<td>1 dose</td>
<td>NA</td>
<td>NA</td>
<td>14 days~</td>
</tr>
<tr>
<td>Bharat Biotech</td>
<td>BBV152/ Covaxin®</td>
<td>2 doses</td>
<td>28 days</td>
<td>24 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>CanSinoBIO</td>
<td>Convidecia (AD5.Cov2-S [Recombinant])</td>
<td>Minimum Doses</td>
<td>Recommended Interval Between Doses</td>
<td>Minimum Acceptable Interval Between Doses^</td>
<td>Interval from Completion of Primary Vaccination to Start of Valid Vaccination Status</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------</td>
<td>---------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>1 dose</td>
<td>NA</td>
<td>2 doses</td>
<td>21 days or greater</td>
<td>17 days</td>
<td>14 days~</td>
</tr>
</tbody>
</table>

* Based on the WHO SAGE Interim Recommendations for COVID-19 vaccines under Emergency Use Listing
~ Vaccination status valid until 270 days after the last dose of the primary series. A booster dose of a WHO EUL vaccine should be received at around 5 months after completion of the primary series to extend the validity of vaccination status to beyond 270 days. The booster dose should be received no less than 90 days after the completion of the primary series.
^ Grace period of 4 days provided for most recommended intervals.

Table 2c: Primary vaccination recommendations and minimum acceptable dose intervals for a combination of different WHO EUL vaccines

Heterologous vaccine regimens in COVID-19 naïve persons

<table>
<thead>
<tr>
<th>[Manufacturer] Name of Vaccine</th>
<th>Minimum Doses</th>
<th>Recommended Interval Between Doses</th>
<th>Minimum Acceptable Interval Between Doses^</th>
<th>Interval from Completion of Primary Vaccination to Start of Valid Vaccination Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any two of the following WHO EUL vaccines (W):</td>
<td>2 doses</td>
<td>21 days or greater</td>
<td>17 days</td>
<td>14 days~</td>
</tr>
<tr>
<td>• [Pfizer/BioNTech] BNT162b2/Comirnaty® Tozinameran (INN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• [Moderna] mRNA-1273/Spikevax</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• [Astrazeneca] Vaxzevria/AZD1222 (ChAdOx1-S)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• [Serum Institute of India] Covishield™ (ChAdOx1-S)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• [Bharat Biotech] BBV152/Covaxin®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• [Novavax] NVX-CoV2373/Covovax™/Nuvaxovid™</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For combinations with these vaccines (S):
• [Sinopharm] SARS-CoV-2 Vaccine (VeroCell), Inactivated (InCoV)
• [Sinovac] COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™

<table>
<thead>
<tr>
<th>Combination: First Interval:Second Interval# Sinovac-CoronaVac</th>
<th>Total 3 doses (consisting of 1 or 2 doses of these vaccines)</th>
<th>17 days for both first interval and second interval (*13 days for first interval if first vaccine is Sinovac-CoronaVac)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WSS: 21 days : 28 days</td>
<td></td>
<td>14 days, after Dose 2. Vaccination status valid for 120 days. Immediately after the 3rd dose. Vaccination status valid for 270 days.~</td>
</tr>
<tr>
<td>SWS: 21 days : 21 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSW: 28 days : 90 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinopharm WSS: 21 days : 21 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SWS: 21 days : 21 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSW: 21 days : 90 days</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# Based on national recommendations by the Expert Committee on COVID-19 Vaccination
~ Vaccination status valid until 270 days after the last dose of the primary series. A booster dose of a WHO EUL vaccine should be received at around 5 months after completion of the primary series (3 months if the last dose was a Sinovac-CoronaVac or Sinopharm vaccine) to extend the validity of vaccination status to beyond 270 days. The booster dose should be received no less than 90 days after the completion of the primary series.
^ Grace period of 4 days provided for most recommended intervals.

Note:
• Travellers to Singapore who have received and can provide documentary proof of receiving the vaccinations above will be granted valid status of 30 days.
• Travellers to Singapore with 2 doses of Sinovac-Coronavac/Sinopharm will be granted valid status of 30 days regardless of when they had taken their vaccinations as their country may not have adopted a 3 dose primary series yet.
Table 2d: Primary vaccination recommendations and minimum acceptable dose intervals for persons with a recognised past COVID-19 infection

<table>
<thead>
<tr>
<th>Vaccine regimens in COVID-19 recovered persons</th>
<th>Timing of infection</th>
<th>Doses Recommended / Required</th>
<th>Recommended Intervals from Infection and Between Doses</th>
<th>Minimum Acceptable Intervals^</th>
<th>Interval from Completion of Vaccine Course to Fully Vaccinated Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected when unvaccinated (i.e. no prior vaccine doses), or, Infected after receiving one vaccine dose but without completing a primary vaccination</td>
<td>1 dose of ( W )</td>
<td>Receive vaccination 3 months after infection</td>
<td>Receive vaccination at a minimum of 28 days after infection</td>
<td>14 days after 1 dose ( W ) – vaccination status valid for 270 days*</td>
<td>• 14 days after first dose following infection - vaccination status valid for 120 days after Dose 1. • Immediately after the second dose following infection – vaccination status valid for 270 days*</td>
</tr>
<tr>
<td>Infected after completing a primary vaccination</td>
<td>2 doses of ( S ), or, 1 dose of ( S ) and 1 dose of ( W )</td>
<td>Receive vaccination 3 months after infection with interval between doses: • 28 days between doses of Sinovac-CoronaVac, or, • 21 days between doses of Sinopharm, or, • 21 days or more between a dose of ( W ) and a dose of ( S )</td>
<td>Receive vaccination at a minimum of 28 days after infection, with a minimum interval between doses of: • 13 days between doses of Sinovac-CoronaVac, or, • 17 days between doses of Sinopharm, or, • 17 days between a dose of ( W ) and a dose of ( S )</td>
<td>Vaccination status valid for 270 days after last dose, or 180 days after infection, whichever is later*</td>
<td></td>
</tr>
<tr>
<td>Infected after receiving a partial vaccination series of two dose amounting to one of the following:</td>
<td>No further doses required.</td>
<td>Nil</td>
<td>Nil</td>
<td>Vaccination status valid for 270 days after the date of locally documented infection*,</td>
<td></td>
</tr>
<tr>
<td><strong>S-I, S-W-I, W-S-I</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**W** refers to the following WHO EUL Vaccine:
- [Pfizer/BioNTech] BNT162b2/COMIRNATY® Tozinameran (INN)
- [Moderna] mRNA-1273/Spikevax
- [Astrazeneca] Vaxzevensia/AZD1222 (ChAdOx1-S)
- [Serum Institute of India] Covishield™ (ChAdOx1-S)
- [Bharat Biotech] BBV152/Covaxin®
- [Novavax] NVX-CoV2373/Covovax™/Nuvaxovid™

^ Grace period of 4 days provided for most recommended intervals

**S** refers to the following vaccines:
- [Sinopharm] SARS-CoV-2 Vaccine (VeroCell), Inactivated (InCoV)
- [Sinovac] COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™

**I** refers to previous infection

*From 1 Jun 2022, recovered persons would need to receive the booster dose to maintain their vaccinated status beyond the validity period indicated in the rightmost column. This should be from about five months after the last dose of their primary vaccination series and should be received at least 28 days after the infection.*
Annex C

Modes of Verification for Vaccination-Differentiated SMMs

The full list of acceptable documents can be found at [https://go.gov.sg/acceptabledocs](https://go.gov.sg/acceptabledocs). For more information on vaccination statuses and records, please visit [https://go.gov.sg/postvacc](https://go.gov.sg/postvacc).

<table>
<thead>
<tr>
<th>An individual is eligible if:</th>
<th>Modes of verification (recommended in bold)</th>
</tr>
</thead>
</table>
| A. An individual is fully vaccinated | 1. TT app or TT token to be scanned against the SE (Business) app  
2. TT app  
3. HealthHub app  
4. Local physical vaccination card & government-issued photo identification card |
| Vaccinated in Singapore | 1. TT app or TT token to be scanned against the SE (Business) app  
2. TT app  
3. HealthHub app |
| Vaccinated overseas with full regimen of WHO EUL vaccines and do not have their vaccination records ingested in MOH’s national IT systems | 1. TT app or TT token to be scanned against the SE (Business) app  
2. TT app |
| Vaccinated overseas with full regimen of WHO EUL vaccines and had their vaccination records ingested in MOH’s national IT systems | 1. TT app or TT token to be scanned against the SE (Business) app  
2. TT app  
3. HealthHub app |
| B. [UPDATED] An individual has recovered from COVID-19 in Singapore within 180 days and not fully vaccinated | Produce either one of the following with their government-issued photo identification card:  
1. TT app or SE  
2. HealthHub app  
3. PET exemption notice; or  
4. Discharge/recovery memo if it indicates the date of the 1st PCR/ART positive result obtained at approved test providers |
| Recovered from COVID-19 within 180 days of starting from the day of the first positive PCR test result, or positive ART result obtained at approved test providers | 1. Recovery memo if it indicates the date of the 1st local positive serology test result attributable to infection and not past vaccination |
| Recovered from COVID-19 within 180 days of starting from the day of the first local positive serology test result attributable to infection and not past vaccination | 1. Recovery memo if it indicates the date of the 1st local positive serology test result along with their government-issued photo identification card. |

2 SC/PR/LTPHs who are vaccinated overseas must first be tested serology positive at a medical provider before their vaccination records are recognised by MOH. SE (Business) App and TT App will only be able to display their vaccination status after the clinic has provided the data to National Immunisation Registry (NIR). Vaccinated STPHs with vaccination certificates will be recognised and shown as “Vaccinated” on SE (Business) App and TT Apps for a period of 30 days. Beyond that, STPH are recommended to undergo a serology test in order for the vaccination status to continue to be recognised and shown as “Vaccinated” on SE (Business) App and TT Apps. More details on the process, including the list of the approved providers, can be found on MOH’s Post Vaccination Matters website.

3 Serology tests and memos can be obtained from approved providers.
### Child aged 12 years and below (i.e. born in or after the year 2010)\(^4\)

- Proof of identity for children ≥ 7 years old (e.g. student concession card)

### Individuals who are medically ineligible for vaccines under the National Vaccination Programme

1. **TT app or TT token to be scanned against the SE (Business) app**
2. **TT app**
3. HealthHub app
4. Hardcopy of the doctor-certified memo\(^5\) (based on the template provided by MOH) along with their government-issued photo identification card.

---

\(^4\) Children born in 2009 who turn 13 in 2022 will need to be fully vaccinated to enter venues and participate in activities with vaccination-differentiated SMMs from 1 March 2022.

\(^5\) Refer to para 4(d).
**Annex D**

**Processes to be Implemented by Event Organisers and Relevant Enterprises**  
**Implementing Vaccination-Differentiated SMMs**

1. Event organisers and relevant enterprises must verify that an individual fulfils the eligibility requirements before allowing him/her to enjoy vaccination-differentiated SMMs (e.g. entry into and attendance of event or dining in at food and beverage establishments where vaccination-differentiated SMMs are required).

2. Checks by event organisers and relevant enterprises should be limited to the verification of the individual’s eligibility status for vaccination-differentiated SMMs, and the information shared by event attendees or customers should not be used or stored for other purposes.

3. Event organisers and relevant enterprises that implement vaccination-differentiated SMMs should put up clear signages to inform event attendees and customers on this and verify their eligibility status. They are encouraged to inform individuals of the documents they will need to provide ahead of their visit where possible.

**Diagram 1. Flowchart summarising the process by which event organisers and relevant enterprises can check if an individual is eligible for vaccination-differentiated SMMs**

*When checking in via SafeEntry (Business) App, a “Check in recorded” screen in green is shown if the individual is eligible for VDS. (Note: only for venues that have enabled VDS Check with Auto Check-ins switched on)*
Using SafeEntry (Business) App

4. Event organisers and relevant enterprises that have deployed the SafeEntry (Business) App to facilitate check-ins should ensure that the app has been updated to the latest version. The vaccination-differentiated SMMs check feature should be enabled for the venue via their SafeEntry account, before they are able to verify vaccination status and test result\(^6\). The auto check-in function is switched on by default to facilitate faster check-ins for individuals who are eligible for vaccination-differentiated SMMs. Event organisers and relevant enterprises should switch off auto check-ins if there is a need to visually verify visitors’ vaccination status or test result or test validity period.

5. The SafeEntry (Business) App check-in process also provides the last four alphanumeric characters of the person’s NRIC/FIN which can help authenticate the identity of the individual checking-in to the event or activity. The eligibility criteria, illustrated using the SafeEntry (Business) App icons, can be found in Diagram 2 below.

![Diagram 2: Eligibility for Vaccination-Differentiated SMMs](image)

6. The event organisers and relevant enterprises may use (i) the Scan Token QR mode within the SafeEntry (Business) App or (ii) 2D scanner connected to a PC/laptop to scan the TraceTogether Token’s QR code. In extenuating circumstances, NRIC/FIN can also be scanned at the discretion of the business. Individuals should be reminded to replace Tokens that are faulty or out of battery.

\(^6\) Please see the user guide at [https://go.gov.sg/status-check](https://go.gov.sg/status-check) for step-by-step instructions.
Using other modes for eligibility checks

7. Event organisers and relevant enterprises may ask individuals to show their vaccination status or test status on their TraceTogether or HealthHub App. Event organisers and relevant enterprises should ensure that the individual is not displaying a screenshot by requesting individuals to click on other icons or “refresh” button within the app. Event organisers and relevant enterprises must ensure that individuals who show their vaccination status via the TraceTogether app have completed SafeEntry check-in.

8. Please refer to the full list of acceptable documents here.

9. Event organisers and relevant enterprises must not recognise any other documents, copies, or any other variations in format and should verify that acceptable documents provided for entry (e.g. Discharge Memo, PET Exemption Memo, etc.) belongs to the individual, i.e. NRIC/FIN on the document matches the NRIC/FIN on the government-issued photo identification card. Hardcopy overseas vaccination certificates will not be accepted for vaccination-differentiated SMMs.